ChemicalBook > Product Catalog >API >Antibiotics >Rifamycin drugs >Rifampicin


Rifampicin Suppliers list
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Products Intro: Product Name:Rifampicin
Purity:97% Package:770/KG
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Rifampicin
Purity:99% Package:100g,500g,1KG,10KG,100KG
Company Name: Shanghai Bojing Chemical Co.,Ltd.
Tel: +86-21-37122233
Products Intro: Product Name:Rifampicin
Purity:99% Package:1Kg;25kg/ Drum or as customer request
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: CAS:13292-46-1
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Products Intro: Product Name:Rifampicin

Lastest Price from Rifampicin manufacturers

  • rifampicin
  • US $10.00 / KG
  • 2019-01-15
  • CAS:13292-46-1
  • Min. Order: 10KG
  • Purity: 99%
  • Supply Ability: 10MT
  • Rifampicin
  • US $7.00 / kg
  • 2018-12-24
  • CAS: 13292-46-1
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100KG
  • Rifampicin
  • US $1.00 / kg
  • 2018-12-24
  • CAS:13292-46-1
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: Customized
Rifampicin Basic information
Inhibitor of Nucleic Acid Synthesis
Product Name:Rifampicin
Synonyms:,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,1///;2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2-h)-dione,5,6;3-(((4-methyl-1-piperazinyl)imino)methyl)-rifamyci;3-((4-methyl-1-piperazinyl)iminomethyl)rifamycinsv;8-(((4-methyl-1-piperazinyl)imino)methyl)rifamycinsv;8-(4-Methylpiperazinyliminomethyl)rifamycinSV;8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins;RIFAMPIN ''LEPETIT''
Product Categories:RIFADIN;antibiotic;Antibiotics;Organics;Antitubercular;Antibiotics for Research and Experimental Use;Biochemistry;Others (Antibiotics for Research and Experimental Use);Antibiotic Explorer;Intermediates & Fine Chemicals;Pharmaceuticals;Isotope Labeled Compounds;Peptide Synthesis/Antibiotics;Chiral Reagents;Isotope Labelled Compounds
Mol File:13292-46-1.mol
Rifampicin Structure
Rifampicin Chemical Properties
Melting point 183°C (dec.)
Boiling point 761.02°C (rough estimate)
density 1.1782 (rough estimate)
refractive index 1.6000 (estimate)
storage temp. 2-8°C
solubility chloroform: soluble50mg/mL, clear
pka1.7, 7.9(at 25℃)
form crystalline
color faint red to very dark red
Water Solubility Soluble in DMSO or methanolSoluble in water, ethyl acetate, chloroform, methanol, tetrahydrofuran and dimethyl sulfoxide.
Merck 14,8216
BRN 5723476
EPA Substance Registry SystemRifamycin, 3-[[(4-methyl-1-piperazinyl) imino]methyl]-(13292-46-1)
Safety Information
Hazard Codes Xn,Xi
Risk Statements 22-36/37/38-36/38
Safety Statements 26-36-37/39
WGK Germany 3
RTECS VJ7000000
HS Code 29419000
Hazardous Substances Data13292-46-1(Hazardous Substances Data)
ToxicityLD50 in mice, rats (mg/kg): 885, 1720 orally; 260, 330 i.v.; 640, 550 i.p. (Fürész)
MSDS Information
Rifampicin Usage And Synthesis
Inhibitor of Nucleic Acid SynthesisRifampicin and other compounds of the ansamycin group specifically inhibit DNA-dependent RNA polymerase; that is, they prevent the transcription of RNA species from the DNA template. Rifampicin is an extremely efficient inhibitor of the bacterial enzyme, but fortunately eukaryotic RNA polymerase is not affected. RNA polymerase consists of a core enzyme made up of four polypeptide subunits, and rifampicin specifically binds to the β subunit where it blocks initiation of RNA synthesis, but is without effect on RNA polymerase elongation complexes. The structural mechanism for inhibition of bacterial RNA polymerase by rifampicin has recently been elucidated. The antibiotic binds to the β subunit in a pocket which directly blocks the path of the elongating RNA chain when it is two to three nucleotides in length. During initiation the transcription complex is particularly unstable and the binding of rifampicin promotes dissociation of short unstable RNA DNA hybrids from the enzyme complex. The binding pocket for rifampicin, which is absent in mammalian RNA polymerases, is some 12 Å away from the active site.
Chemical PropertiesRed to Orange Crystalline Solid
UsesSemisynthetic antibiotic. Antibacerial (tuberculostatic)
Usesantibacterial (tuberculostatic)
DefinitionChEBI: A member of the class of rifamycins that is a a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (previously known as Amycolatopsis mediterranei and Streptomyces mediterranei)
Brand nameRifadin (Sanofi Aventis); Rimactane (Actavis).
Antimicrobial activityIt exhibits potent activity in vitro against Gram-positive cocci, including methicillin-resistant staphylococci (MIC <0.025–0.5 mg/L) and penicillinresistant pneumococci. Enterococci are less susceptible. Gram-positive bacilli, including Bacillus spp., Clostridium difficile, Corynebacterium spp. and Listeria monocytogenes, are highly susceptible (MIC 0.025–0.5 mg/L). The pathogenic Neisseria and Moraxella spp. are also highly susceptible.
Enteric Gram-negative bacteria are generally less sensitive (MIC 1–32 mg/L), but Bacteroides fragilis is highly susceptible. Among other Gram-negative bacilli, Haemophilus influenzae, H. ducreyi, Flavobacterium meningosepticum and Legionella spp. are highly susceptible (MIC <0.025–2 mg/L). Chlamydia trachomatis and Chlamydophila psittaci are inhibited by low concentrations (0.025–0.5 mg/L).
Most strains of M. tuberculosis, M. kansasii and M. marinum are inhibited by <0.01–0.1 mg/L, but M. fortuitum and members of the M. avium complex are resistant. M. leprae is highly sensitive.
Rifampicin is active against some eukaryotic parasites through inhibition of the prokaryote-like polymerase of kinetoplasts or mitochondria. Maturation of Plasmodium falciparum is inhibited by 2–10 mg/L; at higher concentrations Leishmania spp. are also inhibited.
High concentrations inhibit growth of a variety of poxviruses by interference with viral particle maturation; viral reverse transcriptase is unaffected.
Acquired resistanceMost large bacterial populations contain resistant mutants, which readily emerge in the presence of the drug and can emerge during treatment. The mutation rate to resistance in Staph. aureus, Str. pyogenes, Str. pneumoniae, Esch. coli and Proteus mirabilis is about 10–7 and that to M. tuberculosis and M. marinum 10–9–10–10. Primary resistance in M. tuberculosis remained low for many years, but is increasing.
Resistance is of the one-step type, and several classes of mutants exhibiting different degrees of resistance can be selected by exposing a large population to a relatively low concentration of the drug. Some of these mutants may be susceptible to other rifamycin derivatives.
Resistance is due to a change in a single amino acid of the β subunit of DNA-dependent RNA polymerase, which no longer forms a stable complex with rifampicin. It is not transferable and there is no cross-resistance with any other antibiotic class. The susceptible strains of the gastrointestinal flora become rapidly resistant during rifampicin treatment without alteration in the flora composition, and revert to susceptibility within a few weeks of cessation of treatment.
Pharmaceutical ApplicationsRifampin (USAN). Molecular weight: 822.95.
A semisynthetic derivative of rifamycin SV, available for oral administration or intravenous infusion and in several combined formulations with other antimycobacterial drugs. It is poorly soluble in water, but soluble in organic solvents.
PharmacokineticsOral absorption:>90%
Cmax300 mg oral :4 mg/L after 2 h
600 mg oral:10 mg/L after 2 h
Plasma half-life:2.5 h
Volume of distribution:1.5 L/kg
Plasma protein binding:80%
Rifampicin is virtually completely absorbed when administered orally, but substantial differences in blood levels have been reported in comparisons of capsules or tablets from different manufacturers. Peak plasma levels differ noticeably between individuals. Food affects absorption, the peak plasma levels being delayed and about 2 mg/L lower after a meal. Although the AUC and the length of time for which effective antibacterial levels are maintained are little affected, it is preferable that patients take the drug before meals.
Intravenous administration produces AUCs and elimination half-lives similar to those obtained after oral doses.
The lipid solubility of the drug facilitates its distribution. It is widely distributed in the internal organs, bones and fluids, including tears, saliva, ascitic fluid and abscesses. It penetrates into cells and is active against intracellular bacteria. Low concentrations are found in the cerebrospinal fluid (CSF), but these are substantially higher when the meninges are inflamed. Concentrations around 60% of the simultaneous plasma value were found in the heart valves of patients receiving a 600 mg dose before surgery.
Rifampicin is metabolized principally to its desacetyl derivative, which is also antimicrobially active, and this process is accelerated by its stimulatory effect on hepatic microsomal enzymes. As a consequence, hepatic clearance increases on continuous administration and, especially with high doses, the serum half-life becomes shorter after a few days of treatment.
The main route of elimination is secretion into the bile, a process that is dose dependent, being efficient at low dosage but limited at high dosage. As a result, the dose determines the proportion excreted via the bile or passing the liver to be excreted in the urine. Because there is a limit to the rate at which the liver can deliver the drug to the bile, the elimination half-life after a 600 mg dose rises to 3 h and may be as long as 5 h with a 900 mg dose.
The desacetyl compound is mainly found in the bile, where the parent compound accounts for only 15% of the total. Plasma levels are increased by hepatic insufficiency and biliary obstruction, and by probenecid, which depresses hepatic uptake. The drug escaping biliary excretion appears in the urine, to which it imparts an orange–red color, the parent compound and the desacetyl metabolites being present in about equal proportions. The plasma concentration and half-life are not significantly affected by renal failure. The drug is not removed by hemodialysis.
Clinical UseTuberculosis (in combination with other antituberculosis agents; see Ch. 58)
Leprosy (in combination with other antileprotic agents; see Ch. 57)
Serious infection with multiresistant staphylococci and pneumococci (in combination with a glycopeptide)
Elimination of nasopharyngeal carriage of Neisseria meningitidis and H. influenzae.
Side effectsRifampicin is relatively non-toxic, even when administered for a long period (as in the treatment of tuberculosis). However, several unwanted effects, including pink staining of soft contact lenses, are associated with its use. Other reactions can be divided into those associated with daily or intermittent administration, and those found only with intermittent therapy.
Safety ProfileSuspected carcinogen with experimental neoplastigenic and teratogenic data. Poison by intraperitoneal and intravenous routes. Moderately toxic to humans by ingestion. Moderately experimentally toxic by ingestion and subcutaneous routes. Human systemic effects by ingestion: conjunctiva irritation, iritis (inflammation of the iris), other eye effects, dermatitis. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Purification MethodsThis macrolide antibiotic crystallises form Me2CO in red-orange plates. It has UV max at 237, 255, 334, and 475nm ( 33,200, 32,100, 27,000 and 15,400) at pH 7.38. It is stable in Me2SO and H2O and is freely soluble in most organic solvents but slightly soluble in H2O at pH <6. [Binda et al. Arzneim.-Forsch 21 1907 1971.] It inhibits cellular RNA synthesis without affecting DNA [Calvori et al. Nature 207 417 1965].
Rifampicin Preparation Products And Raw materials
Raw materialsSulfuric acid -->tert-Butylamine
Preparation ProductsRifapentine
Tag:Rifampicin(13292-46-1) Related Product Information
RIFAMPIN, [4-METHYLPIPERAZINE-3H]- RIFAMYCIN SV-3 FORMYL RIFAMYCIN SODIUM R 761 Rifametane N-Demethyl Rifampin Rifamycin, 4-O-(carboxymethyl)- Rifampicin Thiophanate-methyl Methyl Methyl acetate RIFAMYCIN SV Kresoxim-methyl Methyl salicylate Rifamycin sodium salt Parathion-methyl Methyl bromide 2-[[[[(4-Methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]benzoic acid methyl ester